Risk factors
Nexentis Technologies (NXTS) risk factors
Item 1A of every Nexentis Technologies Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
44 risks, 4 new, 31 dropped, 3 reworded since the prior year. Nexentis now emphasizes MitoCareX’s preclinical oncology pipeline, unproven MITOLINE™ algorithm, and no commercial products or revenue.
Filed Mar 31, 2026 - FY2024 10-K risk factors
71 risks. Nexentis faces significant accumulated losses and capital needs while transitioning its agricultural and food treatment products to commercial markets. Regulatory approvals across multiple countries and customer adoption through lengthy pilot testing cycles are critical to success. The company relies heavily on limited contract manufacturers like Zohar Dalia and maintains a joint venture in solar energy with Solterra.
Filed Mar 31, 2025